News - 03 Dec `20FDA Meeting on Vitiligo: New Date

New

UPDATE: FDA is announcing a new date for the meeting. The public meeting will be held on March 8, 2021 from 10 a.m. to 2:30 p.m. EST, in a virtual (online only) format. Please save this date and time if you are interested in attending this public meeting.

US Food and Drug Administration (FDA) is conducting its first public meeting on Patient-Focused Drug Development for Vitiligo. The meeting is intended to allow FDA to obtain patient perspectives on the impact of vitiligo, including on daily life, patient views on treatment approaches, and decision factors taken into account when selecting a treatment. 

Additional information about the meeting can be found on the meeting webpage. The webpage will be updated as meeting materials are developed, and registration will be available closer to the meeting date.

Please email the PFDD Staff at patientfocused@fda.hhs.gov if you have any questions.

 



      FAQOther Questions

      • How smoking affects vitiligo?

        Smoking is a common habit linked to numerous health risks, affecting multiple body systems and increasing various disease risks, including respiratory and cardiovascular issues....

      • Pyrostegia venusta as a folk medicine for vitiligo?

        Pyrostegia venusta, also known as “flame vine” or “cipó-de-são-joão,” is a neotropical evergreen vine native to Brazil. It thrives in fields, coastal areas, forest edges, and ro...

      • What are risks of oral and topical corticosteroids?

        Corticosteroid drugs (like hydrocortisone, and others) are often used for treating vitiligo. By mimicing the effects of hormones your body produces naturally in your adrenal gla...